The U.S. single-use bioprocessing market size was exhibited at USD 8.15 billion in 2023 and is projected to hit around USD 35.13 billion by 2033, growing at a CAGR of 15.73% during the forecast period 2024 to 2033.
Report Coverage | Details |
Market Size in 2024 | USD 9.43 Billion |
Market Size by 2033 | USD 35.13 Billion |
Growth Rate From 2024 to 2033 | CAGR of 15.73% |
Base Year | 2023 |
Forecast Period | 2024-2033 |
Segments Covered | Product, Workflow, End-use |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Regional Scope | U.S. |
Key Companies Profiled | Sartorius AG; Danaher; Thermo Fisher Scientific, Inc.; Merck KGaA; Avantor, Inc.; Eppendorf SE; Corning Incorporated; Lonza; PBS Biotech, Inc.; Meissner Filtration Products, Inc. |
The surge in demand for biopharmaceuticals in the country has led suppliers to enhance their offerings of disposable systems, catering to the evolving needs of end-users. Notably, significant technological advancements in bioreactor designs, mixing systems, and fluid assemblies are driving the adoption of single-use technology in biopharmaceutical developments.
The U.S. single-use bioprocessing market accounted for nearly 29% of the global single-use bioprocessing market, dominating the industry by a landslide. This trend aligns with the country’s focus on capacity expansion for biopharmaceutical manufacturing and the commercial advantages offered by single-use equipment, such as cost-effectiveness and reduced contamination risk.
The biopharmaceutical sector in the U.S. is known for its high research and development intensity, driving the adoption of single-use technologies for a more flexible and efficient approach, leading to substantial revenue growth. Moreover, the U.S. FDA foresees approving 10 to 20 cell & gene therapy products annually by 2025, based on current clinical success rates and a promising product pipeline. This is expected to accelerate the adoption of disposable containers and equipment in bioprocessing, addressing the demand-supply gap. Many companies are enhancing their manufacturing capabilities to meet the rising demand.
Efforts are underway in the country to standardize the use of single-use technology and address challenges related to extractables and leachables. Suppliers are actively working on enhancing single-use bioreactor working volumes to meet the increasing market demand. These initiatives are expected to drive further adoption of disposable systems in biopharmaceutical development.
A June 2021 White House report suggested boosting funding for advanced manufacturing technologies by the Department of Health and Human Services, the Department of Defense, and other agencies to enhance continuous manufacturing and biomanufacturing of APIs, signaling a rising trend towards disposable biomanufacturing technologies. Moreover, the market is benefitting from a diverse range of disposable systems tailored to meet specific customer requirements. This diversity in product offerings, including media optimization, cell culturing, filtration, and fill/finish stages, is projected to boost the adoption of single-use technology in the country’s biopharmaceutical sector.
Simple & peripheral elements led the market in 2023 and accounted for over 45% of the revenue share generated. Moreover, the segment is also expected to register the fastest CAGR over the forecast period. This is attributable to the increasing importance of bioprocessing in manufacturing. Besides the production reactor, other accessories necessary for biopharma manufacturing also fall under this category.
Tubing, filters, connectors, and transfer systems were the most consumed products within the segment in 2023. In addition to these products’ implementation by biomanufacturers, they are also applied in lab scale settings and academic institutes due to availability and adoption of various scaled down single-use solutions. Thus, the larger customer base and enhanced sterility impacts segment growth positively.
The apparatus & plants segment is expected to witness lucrative growth from 2024 to 2033, largely due to the diverse range of single-use bioreactors on offer. In line with the trend towards single-use solutions, a significant number of such bioprocessing products have been launched over time. Besides bioreactors, other systems like filtration, mixing, and chromatography have also been made commercially available for biopharmaceutical processing.
Upstream bioprocessing dominated the market in 2023, generating nearly 58.15% of the total revenue share generated owing to the wide implementation of single-use bioreactors in bioprocessing. It is also anticipated to have the fastest CAGR over the forecast period, which is attributable to the wide usage of other disposables systems in the segment, such as single-use bags, mixing systems, and sensors. Continuous developments and betterment in technologies have also been driving the expected growth. For instance, in May 2023, Danaher Corporation merged Cytiva and Pall under the Cytiva brand. This merger simplified customer access to bioprocess technologies and services. The combined entity offered a broad product portfolio across the bioprocess spectrum, thereby facilitating the development of novel therapeutics.
The fermentation sector is expected to experience rapid expansion during the forecast period, driven by substantial advancements that boost revenue. The fundamental requirement for any fermentation bioprocess production is to uphold ideal manufacturing conditions like oxygen, temperature, pH, and other factors in the fermenter. Technological improvements have led to the development of optimized and engineered single-use fermenters (SUFs), contributing to this segment’s growth.
Biopharmaceutical manufacturing occupied the largest market revenue share in 2023 at approximately 57.6%. The rise in biopharmaceutical manufacturing is attributed to the substantial commercial success of biologics. Bio manufacturers, the primary users of single-use technologies, can be divided into in-house manufacturers and contract organizations. Contract manufacturing/research services provide numerous advantages that are increasing their adoption in the bioprocessing market. Conversely, in-house manufacturing is an appropriate choice for companies with substantial capital, offering benefits like internal process troubleshooting and quick supply due to flexible batch planning.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. single-use bioprocessing market
Product
Workflow
End-use